Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas-Reference-Cited by-同舟云学术

Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas

Published:2015-11-27 Issue:3 Volume:126 Page:519-525
ISSN:0167-594X
Container-title:Journal of Neuro-Oncology
language:en
Short-container-title:J Neurooncol

Author:

Losa Marco,Bogazzi Fausto,Cannavo Salvo,Ceccato Filippo,Curtò Lorenzo,De Marinis Laura,Iacovazzo Donato,Lombardi Giuseppe,Mantovani Giovanna,Mazza Elena,Minniti Giuseppe,Nizzoli Maurizio,Reni Michele,Scaroni Carla

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Clinical Neurology,Neurology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11060-015-1991-y.pdf

Reference23 articles.

1. Knizhnik AV, Roos WP, Nikolova T, Quiros S, Tomaszowski KH, Kaina B (2013) Survival and death strategies in glioma cells: autophagy, senescence and apoptosis triggered by a single type of temozolomide-induced DNA damage. PLoS ONE 8:e55665

2. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L (2007) Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56:275–287

3. Kesari S, Schiff D, Drappatz J, LaFrankie D, Doherty L, Macklin EA, Muikansky A, Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G, Ramakrishna N, Black PM, Wen PY (2009) Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 15:330–337

4. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomized phase III study: 5-year analysis of the EORT-NCIC trial. Lancet Oncol 10:459–466

5. Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, Dunder K, Koziovacki G, Orlefors H, Sigurd M, Oberg K, Eriksson B, Skogseid B (2007) Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13:2986–2991

Cited by 112 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temozolomide (TMZ) in the Treatment of Glioblastoma Multiforme—A Literature Review and Clinical Outcomes;Current Oncology;2024-07-12

2. Establishment of Human Pituitary Neuroendocrine Tumor Derived Organoid and Its Pilot Application for Drug Screening;The Journal of Clinical Endocrinology & Metabolism;2024-04-24

3. Temozolomide for aggressive pituitary tumors:-A literature review;Asian Journal of Surgery;2024-02

4. Pharmacological Treatment of Non-Functioning Pituitary Adenomas;Archives of Medical Research;2023-12

5. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement;Nature Reviews Endocrinology;2023-09-05